Pharmaceuticals occupiers in Paris typically cluster in La Défense, plan ~220 sqft per seat at high-end fit-out ($215–310/sqft), and pay around 95 EUR/sqft ($103 USD) on Class A.
Pharmaceuticals occupiers in Paris typically cluster in La Défense, plan ~220 sqft per seat at high-end fit-out">fit-out ($215–310/sqft), and pay around 95 EUR/sqft ($103 USD) on Class A.
Pharmaceuticals occupiers in Paris typically anchor in La Défense. Banks (Société Générale, BNP Paribas headquarters), insurance, energy majors, professional services.
Class A rent in Paris runs 95 EUR/sqft ($103 USD) on a 9-year lease with 18 months free. Prime submarkets sit at or modestly above the city index.
Typical pharmaceuticals fit-out targets high-end specification at $215–310/sqft. Branded reception, full client-facing programming, premium furniture, and specialist AV are standard.
Plan around 220 sqft per seat blended (workstation + circulation + amenity). A 100-headcount pharma office in Paris typically targets 22,000 sqft of leasable area.
Commercial and medical-affairs teams cluster near academic-medical anchors; large floor plates support cross-functional brand teams. Strong financial-services and luxury-brand talent pool. Average all-in compensation indexes 90 vs. New York's 100.
Headline corporate tax: 25%. The bail commercial is the standard lease — 9 years with tenant break rights at year 3 and year 6. Rent is indexed annually to the ILAT or ICC indices. Rent-free of 12-24 months on a 9-year term is standard. Service charges and tax foncière are typically passed through. Restoration to original is the default obligation.
| city | Paris |
|---|---|
| industry | Pharmaceuticals |
| naics | 3254, 5417 |
| preferredSubmarket | La Défense |
| preferredFitoutSpec | High-end |
| fitoutBand | $215–310/sqft |
| sqftPerSeat | 220 |
| classARentLocal | 95 EUR/sqft/yr |
| classARentUsd | $103/sqft/yr |
| vacancyPct | 7.6% |
| typicalLeaseYears | 9 |
| typicalRentFreeMonths | 18 |
| talentIndex | 90 |
| corporateTaxPct | 25% |
Reviewed by Samuel Okafor — EMEA contributing editor. Last updated 2026-04-15. See our methodology and editorial standards.